Journal ArticleDOI
Pharmacokinetics and biodistribution of nanoparticles.
Shyh-Dar Li,Leaf Huang +1 more
Reads0
Chats0
TLDR
Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs.Abstract:
Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The pharmacokinetics (PK) and tissue distribution of the nanoparticles largely define their therapeutic effect and toxicity. Chemical and physical properties of the nanoparticles, including size, surface charge, and surface chemistry, are important factors that determine their PK and biodistribution. The intracellular fate of the nanoparticles after cellular internalization that affects the drug bioavailability is also discussed. Strategies for overcoming barriers for intracellular delivery and drug release are presented. Finally, future directions for improving the PK of nanoparticles and perspectives in the field are discussed.read more
Citations
More filters
Journal ArticleDOI
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
TL;DR: Molecular mechanisms of factors related to the EPR effect, the unique anatomy of tumor vessels, limitations and techniques to avoid such limitations, augmenting tumor drug delivery, and experimental and clinical findings are discussed.
Journal ArticleDOI
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
TL;DR: A historical review of the EPR effect, including its features, vascular mediators found in both cancer and inflamed tissue, and methods of augmentation of theEPR effect are described, that result in better tumor delivery and improved therapeutic effect.
Journal ArticleDOI
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
Daniel Bobo,Kye J. Robinson,Jiaul Islam,Jiaul Islam,Kristofer J. Thurecht,Simon R. Corrie,Simon R. Corrie +6 more
TL;DR: An up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process is provided, and there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials.
Journal ArticleDOI
Nanoscale Metal–Organic Frameworks for Biomedical Imaging and Drug Delivery
TL;DR: Although still at a very early stage of development, NMOFs have already shown great promise as a novel platform for nanomedicine and should allow for the incorporation of other imaging and therapeutic agents and their effective delivery to targeted cells in vivo.
Journal ArticleDOI
Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake.
TL;DR: This study establishes principles for the rational design of clinically useful nanomaterials by investigating the role of size and surface chemistry in mediating serum protein adsorption to gold nanoparticles and their subsequent uptake by macrophages.
References
More filters
Journal Article
A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs
Yasuhiro Matsumura,Hiroshi Maeda +1 more
TL;DR: It is speculated that the tumoritropic accumulation of smancs and other proteins resulted because of the hypervasculature, an enhanced permeability to even macromolecules, and little recovery through either blood vessels or lymphatic vessels in tumors of tumor-bearing mice.
Journal ArticleDOI
Understanding biophysicochemical interactions at the nano–bio interface
Andre E. Nel,Lutz Mädler,Darrell Velegol,Tian Xia,Eric M.V. Hoek,Ponisseril Somasundaran,Fred Klaessig,Vince Castranova,Mike Thompson +8 more
TL;DR: Probing the various interfaces of nanoparticle/biological interfaces allows the development of predictive relationships between structure and activity that are determined by nanomaterial properties such as size, shape, surface chemistry, roughness and surface coatings.
Journal ArticleDOI
Drug Delivery Systems: Entering the Mainstream
TL;DR: There is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics.
Journal ArticleDOI
Renal clearance of quantum dots.
Hak Soo Choi,Wenhao Liu,Preeti Misra,Eiichi Tanaka,John P. Zimmer,Binil Itty Ipe,Moungi G. Bawendi,John V. Frangioni,John V. Frangioni +8 more
TL;DR: This study has precisely defined the requirements for renal filtration and urinary excretion of inorganic, metal-containing nanoparticles and provides a foundation for the design and development of biologically targeted nanoparticles for biomedical applications.
Related Papers (5)
A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs
Yasuhiro Matsumura,Hiroshi Maeda +1 more